Thank you, Cory. Good morning to everybody. This presentation will contain forward-looking statements. So BioMarin is a company that's mainly focused on genetic and serious medical disorders. Our strategy has been to go after high or extremely high unmet medical needs and try to have a large impact on a small patient population. We are kind of the opposite of big pharma – we want to make a big difference in a small patient population instead of a small difference in a large patient population. And we want to be first to market or best in class.